ArticleObesity facts2026
Renin-to-Aldosterone Ratio Is Associated with Ambulatory Blood Pressure Levels and Control in Treated Hypertensive Patients with Overweight or Obesity.
Article in Obesity facts, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCombination therapy, including a renin-angiotensin system inhibitor (RASi) and a thiazide diuretic (TZD) or a calcium channel blocker (CCB), is the first-line approach in hypertension management and modulates circulating markers of the renin-angiotensin-aldosterone system. Excess adiposity may induce renin-aldosterone axis dysregulation and contribute to blood pressure variability and treatment resistance. This study aimed to evaluate the association between the renin-to-aldosterone ratio (RAR) and ambulatory blood pressure monitoring (ABPM) in treated hypertensive patients with central overweight (OW) or obesity (OB).
methodsIn a cross-sectional design, 97 adults with essential hypertension and OW/OB on stable RASi + TZD and/or CCB therapy were matched with 97 normal-weight hypertensive controls. All participants underwent 24-h ABPM and orthostatic direct renin concentration (DRC) and plasma aldosterone concentration (PAC) measurements. RAR was calculated as the ratio between DRC and PAC. For the analyses, values were normalized using natural logarithm (Ln).
resultsLnRAR and LnDRC were inversely associated with 24-h, daytime, and night-time ABP levels in controls, but not in OW/OB patients. However, higher LnRAR and LnDRC values were linked to greater odds of achieving ABP control in both OW/OB and normal-weight for 24h [LnRAR OR 1.74 (1.25-2.42), p = 0.001 in OW/OB], daytime, and night-time periods, whereas LnPAC showed no significant associations. Two-way ANOVA confirmed that patients with controlled ABP had higher median LnRAR and LnDRC values than those with uncontrolled ABP, regardless of weight status (p for interaction >0.05).
conclusionRAR, primarily driven by higher DRC levels and likely linked to a pharmacologic response to RAS inhibition, shows a mechanism-based association with ABP control in treated hypertension, regardless of the presence of visceral OB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.